Impact of Factor V Leiden Polymorphism in Patients with PCOS

Veselin P. Penkov 1 , Katya S. Kovacheva 2 , Georgi M. Golemanov 3 , Galia A. Georgieva 3 , Peter D. Ivanov 3 , Regina S. Komsa-Penkova 3 , and Olamide Ajewole 4
  • 1 Repromed Medical Center, , Pleven, Bulgaria
  • 2 Medical Genetics Section, Faculty of Pharmacy, Medical University, Pleven, Bulgaria
  • 3 Biochemistry Section, Faculty of Pharmacy, Medical University, Pleven, Bulgaria
  • 4 Student III course, Faculty of Medicine, Medical University, Pleven, Bulgaria


The present study aimed to evaluate the impact of factor V Leiden (FVL) polymorphism within the reproductive problems encountered by patients with polycystic ovary syndrome (PCOS). A total of 92 female patients with PCOS and 101 healthy controls were included in the study. Clinical and laboratory parameters were examined. The full history of each patient was taken. Single nucleotide polymorphism rs6025 in F5 was genotyped in PCOS patients and compared to the genotype frequency of the healthy controls. The data were analysed for correlation with infertility and pregnancy loss in PCOS patients. The prevalence of FVL polymorphism was higher, however not significantly, in PCOS patients compared to that of the control group (respectively OR=2.238, 95 % CI 0.777±6.449, p=0.104). The carriers of FVL polymorphism showed a higher rate of primary infertility (30.0% versus 12.5%, OR=3.143, 9 % CI 0.686±14.388, p=0.047) and their total reproductive failure rate was higher (60.5% versus 47.2%, OR=1.819, 95% CI 0.632±9.259, p=0.117). Carriage of FVL polymorphism in PCOS patients is associated with primary infertility and a presumed cause of the further investigations needed to understand the impact of FVL on PCOS. Carriage of FVL polymorphism in PCOS patients is associated with a higher rate of primary infertility, which draws attention to the role of this factor in the aetiology of the PCOS-related subfertility. Further investigations are needed to understand the impact of FVL on PCOS.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016;37(5):467-520. doi:10.1210/er.2015-1104.

  • 2. Melo AS, Dias SV, Cavalli RC, Cardoso VC, Bettiol H, Barbieri MA, et al. Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction. 2015;150(1):R11-24.

  • 3. Zueff LFN, Martins WP, Vieira CS, Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol. 2012;39(3):341-7.

  • 4. Sir-Petermann T, Angel B, Maliqueo M, Carvajal F, Santos JL, Perez-Bravo F. Prevalence of type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia. 2002;45:959-64.

  • 5. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf). 1990;32(2):213-20.

  • 6. Legro RS, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome”. Fertility and Sterility. 2002;78 (3):569-76.

  • 7. Crosignani PG, Nicolosi AE. Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod. 2001;7(1):3-7.

  • 8. Sampson M, Kong C, Patel A, Unwin R & Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol. 1996;45(5):623-9.

  • 9. Lee YH, Song GG. Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;175:8-14.

  • 10. Orio F Jr, Palomba S, Cascella T, Tauchmanova L, Nardo LG, Labella D, et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online. 2004;9(5):505-10.

  • 11. Glueck CJ, Wanga P, Bornovali S, Goldenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism. 2003;52(12):1627-32.

  • 12. Tsanadis G, Vartholomatos G, Korkontzelos I, Avgoustatos F, Kakosimos G, Sotiriadis A, et al. Polycystic ovarian syndrome and thrombophilia. Hum Reprod. 2002;17(2):314-9.

  • 13. T. Kazerooni, F. Ghaffarpasand, N. Asadi, Z. Dehkhoda,M. Dehghankhalili, Y. Kazerooni. Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome: A comparative study. J Chin Med Assoc. 2013;76(5):282-8.

  • 14. Moini A, Tadayon S, Tehranian A, Yeganeh LM, Akhoond MR, Yazdi RS. Association of thrombophilia and polycystic ovarian syndrome in women with history of recurrent pregnancy loss. Gynecol Endocrinol. 2012;28(8):590-593.

  • 15. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7.

  • 16. Komsa-Penkova R, Kovacheva-Kotseva K, Angelova S, Savov A, Semionova M. [Selected methods of DNA analysis and clinical applications]. Pleven: Medical University - Pleven; 2004. Bulgarian

  • 17. Lash GE, Naruse K, Innes BA, Robson SC, Searle RF, Bulmer JN. Secretion of angiogenic growth factors by villous cytotrophoblast and extravillous trophoblast in early human pregnancy. Placenta. 2010;31(6):545-8.

  • 18. Schatz F, Guzeloglu-Kayisli O, Arlier S1, Kayisli UA, Lockwood CJ. The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding. Hum Reprod . 2016;22(4):497-515.

  • 19. Ivanov P, Komsa-Penkova R, Kovacheva K, Konova E, Simeonova M. Influence of factor V LEIDEN carrier on the development of reproductive disorders in different periods of pregnancy. Medical review. 2008;1:68-71.

  • 20. Ivanov P, Konova E, Gecheva S, Cviatkovska C, Izmajlov A, Komsa-Penkova R. et al. Factor V Leiden in assisted reproductive technology. Obstetrics and Gynecology.2013; 6:11-14.

  • 21. Atiomo WU, Condon J, Adekanmi O, Friend J, Wilkin TJ, Prentice AG. Are women with polycystic ovary syndrome resistant to activated protein C? Fertil Steril. 2000;74:1229-1232.


Journal + Issues